GlobeNewswire

Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
03/11/2026
— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . — MIAMI, Nov. 03, 2026 [...]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
03/11/2026
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
03/11/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood [...]
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
03/11/2026
COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501 Q3 2026 revenues of $4.4 billion , a decrease of 2% year-over-year in both U.S. dollars and local currency terms, [...]
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
03/11/2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
03/11/2026
FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
03/11/2026
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Parabilis Medicines to Participate in Upcoming November Investor Conferences
03/11/2026
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by [...]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
03/11/2026
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & [...]
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
03/11/2026
Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1) , compared to Q3 2025 Q3 2026 net income of $58 million or $0.20 per diluted share Q3 2026 Adjusted EBITDA ( 1 ) increased 3.9 [...]
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
03/11/2026
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
03/11/2026
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 [...]
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
03/11/2026
-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue [...]
C4 Therapeutics to Participate in Upcoming November Investor Conferences
03/11/2026
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
03/11/2026
Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability Rezdiffra reaches a major milestone, achieving blockbuster [...]
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
03/11/2026
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
03/11/2026
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
03/11/2026
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
03/11/2026
Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum